ALX Oncology Holdings Inc.
ALXOHealthcareNASDAQBiotechnology · Last scanned Jul 6, 2026
Scan Results
Daily timeframe1 of 4 indicators bearish as of Jul 2
Headquartered within the healthcare sector, ALX Oncology Holdings Inc. focuses on Biotechnology services and products. ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. At a $278.5M market cap, ALX Oncology Holdings Inc. ranks as a micro-cap company within healthcare. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer.
Market Cap
$278.5M
Beta
0.43
P/E (TTM)
—
P/E (Fwd)
-3.85
EPS (TTM)
$-1.49
EPS (Fwd)
$-0.54
ROE
-74.2%
ROA
-36.8%
Cash
$140.3M
Total Debt
$13.0M
Free CF
-$47.8M
52W Change
366.2%
Annual Financials
Cash vs Debt
ALX Oncology Holdings Inc. holds $140.3M in cash against $13.0M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$47.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -74.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
ALXO's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ALXO.